Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

Detalles Bibliográficos
Autores principales: Frey, Nicolas, Bordogna, Walter, Balas, Bogdana, Ruf, Thorsten, Archer, Venice, Guerini, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291499/
https://www.ncbi.nlm.nih.gov/pubmed/34365647
http://dx.doi.org/10.1002/cpt.2373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291499/
https://www.ncbi.nlm.nih.gov/pubmed/34365647
http://dx.doi.org/10.1002/cpt.2373

Ejemplares similares